Pieris Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Pieris Pharmaceuticals is Steve Yoder, benoemd in Dec2014, heeft een ambtstermijn van 9.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.36M, bestaande uit 43% salaris en 57% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde $ 1.19K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.2 jaar en 7 jaar.
Belangrijke informatie
Steve Yoder
Algemeen directeur
US$1.4m
Totale compensatie
| Percentage CEO-salaris | 43.0% |
| Dienstverband CEO | 9.9yrs |
| Eigendom CEO | 0.006% |
| Management gemiddelde ambtstermijn | 5.2yrs |
| Gemiddelde ambtstermijn bestuur | 7yrs |
Recente managementupdates
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$585k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
Compensatie versus markt: De totale vergoeding ($USD 1.36M ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).
Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Steve Yoder (48 yo)
9.9yrs
Tenure
US$1,358,952
Compensatie
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$1.36m | 0.0057% $ 1.2k | |
| Senior VP | 5.2yrs | US$729.04k | 0.018% $ 3.8k | |
| Executive Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Supply Chain Officer | 5.1yrs | geen gegevens | geen gegevens |
5.2yrs
Gemiddelde duur
48yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PIRS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$1.36m | 0.0057% $ 1.2k | |
| Independent Chairman | 7.5yrs | US$94.09k | 0.019% $ 4.0k | |
| Independent Director | 9.9yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 8.2yrs | US$72.58k | 0.019% $ 4.0k | |
| Independent Director | 6.2yrs | US$65.08k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$53.09k | 0% $ 0 | |
| Independent Director | 6.6yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$52.09k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Clinical & Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Clinical & Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Clinical & Scientific Advisory Board | no data | geen gegevens | geen gegevens |
7.0yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PIRS wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).